Clinical trial • Phase I • Oncology
Tuvusertib (M1774) for Advanced solid tumours (metastatic or locally advanced unresectable)
Phase I trial of Tuvusertib (M1774) for Advanced solid tumours (metastatic or locally advanced unresectable). 134 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Advanced solid tumours (metastatic or locally advanced unresectable)
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 30-07-2024
- First CTIS Authorization Date
- 06-08-2024
Trial design
Phase I trial across 2 sites in Spain.
- Target Sample Size
- 134
Recruitment
- Planned Sample Size
- 134
- Recruitment Window Months
- 44
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 134
Spain
- Earliest CTIS Part Ii Submission Date
- 05-07-2024
- Latest Decision Or Authorization Date
- 06-08-2024
- Processing Time Days
- 32
- Number Of Sites
- 2
- Number Of Participants
- 27
Sites
- Site Name
- Hospital Clinic De Barcelona
- Department Name
- Oncology
- Contact Person Name
- Ivan Manuel Victoria Ruiz
- Contact Person Email
- ivictori@recerca.clinic.cat
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Oncology
- Contact Person Name
- Elena Garralda Cabanas
- Contact Person Email
- egarralda@vhio.net
Sponsor
Primary sponsor
- Full Name
- Merck Healthcare KGaA
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Germany
Investigational products
- Investigational Product Name
- Tuvusertib (M1774)
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)